Dapsone oral - Immune Network

Drug Profile

Dapsone oral - Immune Network

Alternative Names: IQ 200; Oral dapsone

Latest Information Update: 06 Mar 2008

Price : $50

At a glance

  • Originator University of British Columbia
  • Class Anti-inflammatories; Antiacnes; Antibacterials; Antileprotics; Antimalarials; Small molecules; Sulfones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 26 Jul 2004 No development reported - Phase-II for Alzheimer's disease in Brazil (PO)
  • 26 Jul 2004 No development reported - Phase-II for Alzheimer's disease in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top